Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome
Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Aims Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different iso...
Saved in:
Published in: | Revista iberoamericana de micologia Vol. 32; no. 1; pp. 34 - 39 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Spain
Elsevier Espana
01-01-2015
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Aims Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii , and their efficacy in an immunosuppressed murine model of disseminated infection. Methods The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8 mg/kg i.v., liposomal amphotericin B at 10 mg/kg i.v., fluconazole at 50 mg/kg, or anidulafungin at 10 mg/kg. Results Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10 mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values. Conclusions Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii , in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy. |
---|---|
AbstractList | Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs.
Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii, and their efficacy in an immunosuppressed murine model of disseminated infection.
The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8 mg/kg i.v., liposomal amphotericin B at 10 mg/kg i.v., fluconazole at 50 mg/kg, or anidulafungin at 10 mg/kg.
Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10 mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values.
Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii, in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy. Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Aims Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii , and their efficacy in an immunosuppressed murine model of disseminated infection. Methods The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8 mg/kg i.v., liposomal amphotericin B at 10 mg/kg i.v., fluconazole at 50 mg/kg, or anidulafungin at 10 mg/kg. Results Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10 mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values. Conclusions Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii , in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy. Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii, and their efficacy in an immunosuppressed murine model of disseminated infection. The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8mg/kg i.v., liposomal amphotericin B at 10mg/kg i.v., fluconazole at 50mg/kg, or anidulafungin at 10mg/kg. Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values. Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii, in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy. Candida guilliermondii es un patógeno emergente, con reducida sensibilidad al fluconazol y a las equinocandinas. Evaluar la actividad in vitro de la anidulafungina, en comparación con la de la anfotericina B y el fluconazol, frente a C. guilliermondii y su eficacia en un modelo animal de infección diseminada. La sensibilidad in vitro se valoró mediante microdilución en caldo y curvas de mortalidad. La eficacia in vivo se evaluó mediante la determinación de la carga fúngica en riñón de ratones inmunosuprimidos con infección diseminada por C. guilliermondii tratados con anfotericina B desoxicolato (0.8mg/kg i.v.), anfotericina B liposomal (10mg/kg i.v.), fluconazol (50mg/kg) o anidulafungina (10mg/kg). La anfotericina B y la anidulafungina mostraron actividad fungicida, mientras que el fluconazol fue fungistático frente a todas las cepas. En el modelo murino, la anfotericina B liposomal redujo para todas las cepas la carga fúngica en riñones, mientras que la anfotericina B desoxicolato, la anidulafungina y el fluconazol fueron efectivas solo en aquellos animales infectados con las cepas de menor valor de concentración mínima inhibitoria (CMI). La anfotericina B liposomal mostró la mayor actividad y eficacia frente a C. guilliermondii, en contraste con el limitado efecto del fluconazol y de la anidulafungina. Se necesitan estudios que incluyan cepas con un rango más amplio de CMI que permitan determinar la relación entre la actividad in vitro y la eficacia de la anidulafungina. |
Author | Mayayo, Emilio Sutton, Deanna A Pastor, Francisco Javier Paredes, Katihuska Guarro, Josep Fothergill, Annette W Capilla, Javier |
Author_xml | – sequence: 1 fullname: Paredes, Katihuska – sequence: 2 fullname: Pastor, Francisco Javier – sequence: 3 fullname: Capilla, Javier – sequence: 4 fullname: Sutton, Deanna A – sequence: 5 fullname: Mayayo, Emilio – sequence: 6 fullname: Fothergill, Annette W – sequence: 7 fullname: Guarro, Josep |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24594291$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAQxy1U1G5LX4AD8gOQxeOk2URCSGgFLVKlHihny7HHu7MkdmQnrfbGo-NogQOHHix7Pv4znt9csjMfPDL2FsQaBNQfDutIelhLAWV2rIVoXrGVhE1ZtNA0Z2wFUIoCKlFfsMuUDkLIWgCcswtZ3bSVbGHFfj3uMeqRMHG90-TTxIc5kke-1d6S1Xw3U98TxiFkmzh5h2ai4N_ziL1eXmlPI-9wekb0Oc6faIqBaz-Rm_1O93zc6zhoE-zR64FMbuUtD_NkwoBv2Gun-4TXf-4r9uPrl8ftXXH_cPtt-_m-MFUDU-EQa2c6fVOVdVVCKRvTuda5jYCuqoWVoMHaDVrbOZPnhka2dYkb18jaWKzKKyZPdU0MKUV0aow06HhUINSCUx3UglMtOBdfxplF706ice4GtP8kf_nlhI-nBMxff8qUVDKE3qClmDEpG-jl-p_-k5uePBnd_8QjpkOYo89QFKgklVDfl4Uu-8xHCJB1-Rvq_aFB |
CitedBy_id | crossref_primary_10_1016_j_diagmicrobio_2016_05_014 crossref_primary_10_1111_myc_12468 crossref_primary_10_1128_AAC_03051_14 |
Cites_doi | 10.1128/JCM.00865-06 10.1007/s15010-002-2131-0 10.1128/AAC.00524-06 10.1016/j.diagmicrobio.2004.07.011 10.1128/CMR.17.2.268-280.2004 10.1128/AAC.48.11.4453-4456.2004 10.1093/jac/dkr143 10.1128/AAC.00500-11 10.1128/JCM.00942-09 10.1128/AAC.50.2.469-473.2006 10.7326/0003-4819-102-1-67 10.1007/s10096-003-1013-4 10.1128/JCM.00937-12 10.1128/JCM.02117-09 10.1111/1469-0691.12041 10.1128/AAC.42.10.2467 10.1007/s101560170033 10.1016/j.drup.2011.01.004 10.1128/JCM.05047-11 10.1128/AAC.50.2.674-684.2006 10.1128/AAC.00111-06 10.1111/j.1439-0507.2010.01960.x 10.1128/AAC.43.9.2116 |
ContentType | Journal Article |
Copyright | Revista Iberoamericana de Micología 2013 Revista Iberoamericana de Micología Copyright © 2013 Revista Iberoamericana de Micología. Published by Elsevier Espana. All rights reserved. |
Copyright_xml | – notice: Revista Iberoamericana de Micología – notice: 2013 Revista Iberoamericana de Micología – notice: Copyright © 2013 Revista Iberoamericana de Micología. Published by Elsevier Espana. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1016/j.riam.2013.10.008 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Terapia antifúngica frente a la infección por Candida guilliermondii en ratones, correlación entre los parámetros farmacodinámicos in vitro y la eficacia in vivo |
EISSN | 2173-9188 |
EndPage | 39 |
ExternalDocumentID | 10_1016_j_riam_2013_10_008 24594291 S1130140614000126 1_s2_0_S1130140614000126 |
Genre | Journal Article |
GroupedDBID | --- 0R~ 0SF 123 2WC 36B 4.4 457 65R AACTN AAEDT AAEDW AAHBH AALRI AAQFI AAXKI AAXUO ABJNI ACGFS ACRLP ADBBV ADCUG ADVLN AEBSH AENEX AEVXI AFJKZ AFKWA AFTJW AFXIZ AIEXJ AIKHN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ AXJTR BAWUL BNPGV CJTIS DIK DU5 EBD EBS EFJIC EJD EMB EML EMOBN FDB FIRID FRP FYGXN GX1 HZ~ MM. O9- OK1 RIG SES SSH SSI SV3 T5K W2D Z7D EFLBG CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c481t-fee6fcba5436431328cbf9ff701b460d21a1dd7eddbfc113182963e7f826cde43 |
ISSN | 1130-1406 |
IngestDate | Thu Sep 26 16:47:26 EDT 2024 Fri Nov 25 08:30:23 EST 2022 Fri Feb 23 02:29:07 EST 2024 Tue Oct 15 22:56:10 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Candida guilliermondii Animal model Modelo animal Infección fúngica Fungal infection |
Language | English |
License | Copyright © 2013 Revista Iberoamericana de Micología. Published by Elsevier Espana. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c481t-fee6fcba5436431328cbf9ff701b460d21a1dd7eddbfc113182963e7f826cde43 |
PMID | 24594291 |
PageCount | 6 |
ParticipantIDs | crossref_primary_10_1016_j_riam_2013_10_008 pubmed_primary_24594291 elsevier_sciencedirect_doi_10_1016_j_riam_2013_10_008 elsevier_clinicalkeyesjournals_1_s2_0_S1130140614000126 |
PublicationCentury | 2000 |
PublicationDate | 2015-01-01 |
PublicationDateYYYYMMDD | 2015-01-01 |
PublicationDate_xml | – month: 01 year: 2015 text: 2015-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Spain |
PublicationPlace_xml | – name: Spain |
PublicationTitle | Revista iberoamericana de micologia |
PublicationTitleAlternate | Rev Iberoam Micol |
PublicationYear | 2015 |
Publisher | Elsevier Espana |
Publisher_xml | – name: Elsevier Espana |
References | Clinical Laboratory Standards Institute (bib0030) 2008 Ullmann, Akova, Herbrecht, Viscoli, Arendrup, Arikan-Akdagli (bib0115) 2012; 18 Graybill, Bocanegra, Najvar, Loebenberg, Luther (bib0050) 1998; 42 Guarro (bib0055) 2011; 66 Pfaller, Diekema, Gibbs, Newell, Ellis, Tullio (bib0090) 2010; 48 Pfaller, Diekema, Andes, Arendrup, Brown, Lockhart (bib0085) 2011; 14 Pfaller, Diekema (bib0080) 2012; 50 Di Bonaventura, Spedicato, Picciani, D’Antonio, Piccolomini (bib0035) 2004; 48 Andes, van Ogtrop (bib0010) 1999; 43 Cantón, Pemán, Sastre, Romero, Espinel-Ingroff (bib0025) 2006; 50 Salas, Pastor, Calvo, Mayayo, Quindós, Carillo (bib0105) 2011; 55 Ortoneda, Capilla, Pastor, Guarro (bib0070) 2004; 50 Barchiesi, Spreghini, Tomassetti, Della Vittoria, Arzeni, Manso (bib0020) 2006; 50 Diekema, Messer, Boyken, Hollis, Kroeger, Tendolkar (bib0040) 2009; 47 Savini, Catavitello, Onofrillo, Masciarelli, Astolfi, Balbinot (bib0110) 2011; 54 Pfaller, Castanheira, Diekema, Messer, Jones (bib0075) 2011; 49 Pfaller, Sheehan, Rex (bib0100) 2004; 17 Pfaller, Diekema, Mendez, Kibbler, Erzsebet, Chang (bib0095) 2006; 44 Arendrup, Horn, Frimodt-Møller (bib0015) 2002; 30 Masala, Luzzati, Maccacaro, Antozzi, Concia, Fontana (bib0065) 2003; 22 Kovacicova, Hanzen, Pisarcikova, Sejnova, Horn, Babela (bib0060) 2001; 7 Vazquez, Lundstrom, Dembry, Chandrasekar, Boikov, Parri (bib0120) 1995; 16 Andes, Safdar, Marchillo, Conklin (bib0005) 2006; 50 Dick, Rosengard, Merz, Stuart, Hutchins, Saral (bib0045) 1985; 102 Wiederhold, Tam, Chi, Prince, Kontoyiannis, Lewis (bib0125) 2006; 50 Salas (10.1016/j.riam.2013.10.008_bib0105) 2011; 55 Clinical Laboratory Standards Institute (10.1016/j.riam.2013.10.008_bib0030) 2008 Ortoneda (10.1016/j.riam.2013.10.008_bib0070) 2004; 50 Barchiesi (10.1016/j.riam.2013.10.008_bib0020) 2006; 50 Ullmann (10.1016/j.riam.2013.10.008_bib0115) 2012; 18 Pfaller (10.1016/j.riam.2013.10.008_bib0085) 2011; 14 Pfaller (10.1016/j.riam.2013.10.008_bib0090) 2010; 48 Guarro (10.1016/j.riam.2013.10.008_bib0055) 2011; 66 Wiederhold (10.1016/j.riam.2013.10.008_bib0125) 2006; 50 Dick (10.1016/j.riam.2013.10.008_bib0045) 1985; 102 Pfaller (10.1016/j.riam.2013.10.008_bib0075) 2011; 49 Graybill (10.1016/j.riam.2013.10.008_bib0050) 1998; 42 Arendrup (10.1016/j.riam.2013.10.008_bib0015) 2002; 30 Pfaller (10.1016/j.riam.2013.10.008_bib0100) 2004; 17 Andes (10.1016/j.riam.2013.10.008_bib0005) 2006; 50 Cantón (10.1016/j.riam.2013.10.008_bib0025) 2006; 50 Diekema (10.1016/j.riam.2013.10.008_bib0040) 2009; 47 Savini (10.1016/j.riam.2013.10.008_bib0110) 2011; 54 Pfaller (10.1016/j.riam.2013.10.008_bib0080) 2012; 50 Pfaller (10.1016/j.riam.2013.10.008_bib0095) 2006; 44 Vazquez (10.1016/j.riam.2013.10.008_bib0120) 1995; 16 Andes (10.1016/j.riam.2013.10.008_bib0010) 1999; 43 Kovacicova (10.1016/j.riam.2013.10.008_bib0060) 2001; 7 Di Bonaventura (10.1016/j.riam.2013.10.008_bib0035) 2004; 48 Masala (10.1016/j.riam.2013.10.008_bib0065) 2003; 22 |
References_xml | – year: 2008 ident: bib0030 article-title: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A3 contributor: fullname: Clinical Laboratory Standards Institute – volume: 43 start-page: 2116 year: 1999 end-page: 2120 ident: bib0010 article-title: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model publication-title: Antimicrob Agents Chemother contributor: fullname: van Ogtrop – volume: 18 start-page: 53 year: 2012 end-page: 67 ident: bib0115 article-title: ESCMID guideline for the diagnosis and management of publication-title: Clin Microbiol Infect contributor: fullname: Arikan-Akdagli – volume: 16 start-page: 849 year: 1995 end-page: 853 ident: bib0120 article-title: Invasive publication-title: Bone Marrow Transplant contributor: fullname: Parri – volume: 102 start-page: 67 year: 1985 end-page: 68 ident: bib0045 article-title: Fatal disseminated candidiasis due to amphotericin B-resistant publication-title: Ann Intern Med contributor: fullname: Saral – volume: 49 start-page: 3800 year: 2011 end-page: 3804 ident: bib0075 article-title: Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of publication-title: J Clin Microbiol contributor: fullname: Jones – volume: 48 start-page: 1366 year: 2010 end-page: 1377 ident: bib0090 article-title: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of publication-title: J Clin Microbiol contributor: fullname: Tullio – volume: 50 start-page: 247 year: 2004 end-page: 251 ident: bib0070 article-title: Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis publication-title: Diagn Microbiol Infect Dis contributor: fullname: Guarro – volume: 22 start-page: 686 year: 2003 end-page: 688 ident: bib0065 article-title: Nosocomial cluster of publication-title: Eur J Clin Microbiol Infect Dis contributor: fullname: Fontana – volume: 50 start-page: 2846 year: 2012 end-page: 2856 ident: bib0080 article-title: Progress in antifungal susceptibility testing of publication-title: J Clin Microbiol contributor: fullname: Diekema – volume: 14 start-page: 164 year: 2011 end-page: 176 ident: bib0085 article-title: Clinical breakpoints for the echinocandins and publication-title: Drug Resist Updat contributor: fullname: Lockhart – volume: 50 start-page: 2719 year: 2006 end-page: 2727 ident: bib0020 article-title: Effects of caspofungin against publication-title: Antimicrob Agents Chemother contributor: fullname: Manso – volume: 50 start-page: 2829 year: 2006 end-page: 2832 ident: bib0025 article-title: Killing kinetics of caspofungin, micafungin, and amphotericin B against publication-title: Antimicrob Agents Chemother contributor: fullname: Espinel-Ingroff – volume: 55 start-page: 4985 year: 2011 end-page: 4989 ident: bib0105 article-title: Anidulafungin in treatment of experimental invasive infection by publication-title: Antimicrob Agents Chemoter contributor: fullname: Carillo – volume: 48 start-page: 4453 year: 2004 end-page: 4456 ident: bib0035 article-title: In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent publication-title: Antimicrob Agents Chemother contributor: fullname: Piccolomini – volume: 44 start-page: 3551 year: 2006 end-page: 3556 ident: bib0095 article-title: , an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program publication-title: J Clin Microbiol contributor: fullname: Chang – volume: 50 start-page: 674 year: 2006 end-page: 684 ident: bib0005 article-title: Pharmacokinetic–pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models publication-title: Antimicrob Agents Chemother contributor: fullname: Conklin – volume: 66 start-page: 1447 year: 2011 end-page: 1466 ident: bib0055 article-title: Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi publication-title: J Antimicrob Chemother contributor: fullname: Guarro – volume: 7 start-page: 45 year: 2001 end-page: 48 ident: bib0060 article-title: Nosocomial fungemia due to amphotericin B-resistant publication-title: J Infect Chemother contributor: fullname: Babela – volume: 50 start-page: 469 year: 2006 end-page: 473 ident: bib0125 article-title: Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis publication-title: Antimicrob Agents Chemother contributor: fullname: Lewis – volume: 47 start-page: 3170 year: 2009 end-page: 3177 ident: bib0040 article-title: In vitro activity of seven systemically active antifungal agents against a large global collection of rare publication-title: J Clin Microbiol contributor: fullname: Tendolkar – volume: 17 start-page: 268 year: 2004 end-page: 280 ident: bib0100 article-title: Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization publication-title: Clin Microb Rev contributor: fullname: Rex – volume: 42 start-page: 2467 year: 1998 end-page: 2473 ident: bib0050 article-title: Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression publication-title: Antimicrob Agents Chemother contributor: fullname: Luther – volume: 30 start-page: 286 year: 2002 end-page: 291 ident: bib0015 article-title: In vivo pathogenicity of eight medically relevant publication-title: Infection contributor: fullname: Frimodt-Møller – volume: 54 start-page: 434 year: 2011 end-page: 441 ident: bib0110 article-title: What do we know about publication-title: Mycoses contributor: fullname: Balbinot – volume: 44 start-page: 3551 year: 2006 ident: 10.1016/j.riam.2013.10.008_bib0095 article-title: Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program publication-title: J Clin Microbiol doi: 10.1128/JCM.00865-06 contributor: fullname: Pfaller – volume: 30 start-page: 286 year: 2002 ident: 10.1016/j.riam.2013.10.008_bib0015 article-title: In vivo pathogenicity of eight medically relevant Candida species in an animal model publication-title: Infection doi: 10.1007/s15010-002-2131-0 contributor: fullname: Arendrup – volume: 50 start-page: 2829 year: 2006 ident: 10.1016/j.riam.2013.10.008_bib0025 article-title: Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00524-06 contributor: fullname: Cantón – volume: 50 start-page: 247 year: 2004 ident: 10.1016/j.riam.2013.10.008_bib0070 article-title: Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2004.07.011 contributor: fullname: Ortoneda – volume: 17 start-page: 268 year: 2004 ident: 10.1016/j.riam.2013.10.008_bib0100 article-title: Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization publication-title: Clin Microb Rev doi: 10.1128/CMR.17.2.268-280.2004 contributor: fullname: Pfaller – volume: 48 start-page: 4453 year: 2004 ident: 10.1016/j.riam.2013.10.008_bib0035 article-title: In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.11.4453-4456.2004 contributor: fullname: Di Bonaventura – volume: 66 start-page: 1447 year: 2011 ident: 10.1016/j.riam.2013.10.008_bib0055 article-title: Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr143 contributor: fullname: Guarro – volume: 55 start-page: 4985 year: 2011 ident: 10.1016/j.riam.2013.10.008_bib0105 article-title: Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1→3)-beta-d-glucan and mannan serum levels, histopathological findings, and in vivo efficacy publication-title: Antimicrob Agents Chemoter doi: 10.1128/AAC.00500-11 contributor: fullname: Salas – volume: 47 start-page: 3170 year: 2009 ident: 10.1016/j.riam.2013.10.008_bib0040 article-title: In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods publication-title: J Clin Microbiol doi: 10.1128/JCM.00942-09 contributor: fullname: Diekema – year: 2008 ident: 10.1016/j.riam.2013.10.008_bib0030 contributor: fullname: Clinical Laboratory Standards Institute – volume: 50 start-page: 469 year: 2006 ident: 10.1016/j.riam.2013.10.008_bib0125 article-title: Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.50.2.469-473.2006 contributor: fullname: Wiederhold – volume: 102 start-page: 67 year: 1985 ident: 10.1016/j.riam.2013.10.008_bib0045 article-title: Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii publication-title: Ann Intern Med doi: 10.7326/0003-4819-102-1-67 contributor: fullname: Dick – volume: 22 start-page: 686 year: 2003 ident: 10.1016/j.riam.2013.10.008_bib0065 article-title: Nosocomial cluster of Candida guilliermondii fungemia in surgical patients publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-003-1013-4 contributor: fullname: Masala – volume: 50 start-page: 2846 year: 2012 ident: 10.1016/j.riam.2013.10.008_bib0080 article-title: Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 publication-title: J Clin Microbiol doi: 10.1128/JCM.00937-12 contributor: fullname: Pfaller – volume: 48 start-page: 1366 year: 2010 ident: 10.1016/j.riam.2013.10.008_bib0090 article-title: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion publication-title: J Clin Microbiol doi: 10.1128/JCM.02117-09 contributor: fullname: Pfaller – volume: 18 start-page: 53 issue: Suppl. 7 year: 2012 ident: 10.1016/j.riam.2013.10.008_bib0115 article-title: ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT) publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12041 contributor: fullname: Ullmann – volume: 42 start-page: 2467 year: 1998 ident: 10.1016/j.riam.2013.10.008_bib0050 article-title: Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.42.10.2467 contributor: fullname: Graybill – volume: 7 start-page: 45 year: 2001 ident: 10.1016/j.riam.2013.10.008_bib0060 article-title: Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors publication-title: J Infect Chemother doi: 10.1007/s101560170033 contributor: fullname: Kovacicova – volume: 14 start-page: 164 year: 2011 ident: 10.1016/j.riam.2013.10.008_bib0085 article-title: Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria publication-title: Drug Resist Updat doi: 10.1016/j.drup.2011.01.004 contributor: fullname: Pfaller – volume: 49 start-page: 3800 year: 2011 ident: 10.1016/j.riam.2013.10.008_bib0075 article-title: Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida publication-title: J Clin Microbiol doi: 10.1128/JCM.05047-11 contributor: fullname: Pfaller – volume: 50 start-page: 674 year: 2006 ident: 10.1016/j.riam.2013.10.008_bib0005 article-title: Pharmacokinetic–pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.50.2.674-684.2006 contributor: fullname: Andes – volume: 50 start-page: 2719 year: 2006 ident: 10.1016/j.riam.2013.10.008_bib0020 article-title: Effects of caspofungin against Candida guilliermondii and Candida parapsilosis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00111-06 contributor: fullname: Barchiesi – volume: 54 start-page: 434 year: 2011 ident: 10.1016/j.riam.2013.10.008_bib0110 article-title: What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast publication-title: Mycoses doi: 10.1111/j.1439-0507.2010.01960.x contributor: fullname: Savini – volume: 43 start-page: 2116 year: 1999 ident: 10.1016/j.riam.2013.10.008_bib0010 article-title: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.43.9.2116 contributor: fullname: Andes – volume: 16 start-page: 849 year: 1995 ident: 10.1016/j.riam.2013.10.008_bib0120 article-title: Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis publication-title: Bone Marrow Transplant contributor: fullname: Vazquez |
SSID | ssj0026011 ssib019627658 |
Score | 2.067951 |
Snippet | Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high... Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs.... |
SourceID | crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 34 |
SubjectTerms | Amphotericin B - pharmacology Animal model Animals Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Candida - drug effects Candida - isolation & purification Candida guilliermondii Candidiasis, Invasive - drug therapy Candidiasis, Invasive - etiology Candidiasis, Invasive - microbiology Communicable Diseases, Emerging - microbiology Drug Evaluation, Preclinical Echinocandins - pharmacology Fluconazole - pharmacology Fungal infection Infección fúngica Infectious Disease Kidney - microbiology Male Mice Microbial Sensitivity Tests Modelo animal Neutropenia - complications Random Allocation Species Specificity |
Title | Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1130140614000126 https://dx.doi.org/10.1016/j.riam.2013.10.008 https://www.ncbi.nlm.nih.gov/pubmed/24594291 |
Volume | 32 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6y4ULAvEqL_nALaSKEzdJj6s2aGEFQuoicbMcP5YuIqmahDM_nXHsOKEr8ZI41GptNbY8X-blmTFCL_OV1vA-0zADKyekhOpwJaBJcx5FpYwi3buyz7fZ-0_5pqDFbDbcJjD2_VdKQx_Q2mTO_gW1_UOhA74DzaEFqkP7p3Q_8D3YvwG_Aqu_aYOvxqGugrVJYJE8uOqMiwUYcg2_dz4aq-c-hyE0bhrCtauCb7v2UAfcBBYBczDJW67itbQX2ttCz3XXiqPiB-boAfTPoI9L4e50iAcmbHbX18vuD-o3XjZ8MPHwlnNdwEo-d82XyVjTWueCuw1E1MFbbuT6eJCyN5co2ejf6cC2a12awEbxChZwtpi6O8jyyN3h83AKYLj2fnHHuUEYh2AtplPWPrpOPYQtn3YOVCvxbTWlG7LEujWuFwANU7KAJIs-DDAfJaePZ9ya2c3k8DEKZHqCbsXA-UyM6ebNhfcAgPXbewCGtbosLhtweDzPbzSliRp0eRfdcfYLPrPAu4dmqrqPvnvQYQc6bEGHHejwz6DDHnSv8BRy2EEOxnEPOTxCDh9DDsYkdpB7gD6-Li7X56G72iMUNCdtqJVKtSj5kiagEpMkzkWpzfFBREqaRjImnEiZKSlLLWC7wAoGSaEyDdawkIomD9FpVVfqMcIi0rSUutRpLqiQSVkqKjMiMxDzuUyiOQqGbWR7W8GFDaGN18xsOjObbvpg0-coG3aaDbnJIE1V417xhhHWxCxiN0g-R0v_T6e9Wq2UAaB-OeMjS1C_upguV6Amkif_-MSn6Pb45jxDp-2hU8_RSSO7Fz0coS3W734AlPLOpQ |
link.rule.ids | 315,782,786,27935,27936 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapies+against+murine+Candida+guilliermondii+infection%2C+relationship+between+in+vitro+antifungal+pharmacodynamics+and+outcome&rft.jtitle=Revista+iberoamericana+de+micolog%C3%ADa&rft.au=Paredes%2C+Katihuska&rft.au=Pastor%2C+Francisco+Javier&rft.au=Capilla%2C+Javier&rft.au=Sutton%2C+Deanna+A.&rft.date=2015-01-01&rft.pub=Elsevier+Espana&rft.issn=1130-1406&rft.volume=32&rft.issue=1&rft.spage=34&rft.epage=39&rft_id=info:doi/10.1016%2Fj.riam.2013.10.008&rft.externalDocID=S1130140614000126 |
thumbnail_m | http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F11301406%2FS1130140614X00057%2Fcov150h.gif |